Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Carol Stiff

- PMLiVE

Moderna granted FDA authorisation for emergency use of BA.4/BA.5-targeting bivalent COVID-19 booster

The application was based on preclinical data and clinical trial data available from a phase 2/3 study evaluation of the company's BA.1 Omicron-targeting bivalent booster candidate

- PMLiVE

Pfizer and BioNTech granted FDA Emergency Use Authorisation for BA.4/BA.5 COVID-19 booster

The companies outlined that the original and bivalent vaccines will be supplied under their existing supply agreement with the US government

- PMLiVE

Novavax’s COVID-19 vaccine candidate approved by MHRA for adolescents aged 12 to 17

Data from an ongoing phase 3 paediatric trial demonstrated Nuvaxovid produced 80% clinical efficacy in this age group

- PMLiVE

Moderna sues Pfizer/BioNTech over COVID-19 vaccine technology

The company believes two key features of its patented mRNA technology platform were copied

- PMLiVE

Study found Pfizer’s Paxlovid only helped over 65s avoid hospitalisation and death

Researchers studied data from 109,000 patients – nearly all of whom had been vaccinated against COVID-19, been previously infected, or both

Engaging KOLs & Gaining Insights in Pharma’s New Normal

Kaitlin Anstett, Senior Medical Advisor at Theratechnologies, shares her unique insights into the way Medical Affairs teams are changing the way they are engaging and interacting with their most important...

Impetus Digital

- PMLiVE

Moderna seeks FDA Emergency Use Authorisation for BA.4/BA.5 COVID-19 booster

The application is based on preclinical data and clinical trial data available from a phase 2/3 study evaluation of the company's BA.1 Omicron-targeting bivalent booster candidate

- PMLiVE

Pfizer and BioNTech release COVID-19 vaccine trial results for children under five

The phase 2/3 trial results showed that the vaccine was 73.2% effective in protecting children aged six months to four years

- PMLiVE

100,000 doses of Janssen’s COVID-19 delivered to Ukraine under COVAX initiative

WHO in Ukraine has trained more than 100 medical workers across the country to conduct further training on the use of Ad26.COV2-S

- PMLiVE

Pfizer and BioNTech seek FDA Emergency Use Authorisation for BA.4/BA.5 COVID-19 booster

The companies have rapidly increased production of the newly developed vaccine and are ready to deliver doses from September

- PMLiVE

Moderna to supply Canada with 12 million doses of Omicron-containing bivalent COVID-19 booster

The company announced in July that it was advancing two bivalent candidates for autumn, based on different population health security strategies in different countries

- PMLiVE

WHO recommends Valneva’s COVID-19 vaccine for those aged between 18 to 50 years old

VLA2001 is a purified, inactivated, and adjuvanted whole virus SARS-CoV-2 vaccine, employing a similar approach to the flu vaccine

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links